Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2024-01-24
Original market date: See footnote 1
2024-01-24
Product name:
NYPOZI
Description:
PREFILLED SYRINGE
DIN:
02521008
Product Monograph/Veterinary Labelling:
Date:
2021-10-08
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
TANVEX BIOPHARMA USA, INC.
10394 Pacific Center Court
San Diego
California
United States
92121
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intravenous , Subcutaneous
Number of active ingredient(s):
1
Schedule(s):
Schedule D , Prescription
Biosimilar Biologic Drug:
Yes
American Hospital Formulary Service (AHFS): See footnote 3
20:16.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
L03AA02 FILGRASTIM
Active ingredient group (AIG) number:See footnote5
0123525003
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| FILGRASTIM | 480 MCG / 0.8 ML |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.